EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors

Leyla Ay iD, Ingrid Pabinger, Matthias Preusser, Anna Sophie Berghoff, Christoph Hoeller, Cihan Ay iD, Florian Moik iD

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Leyla Ay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Inflammation, Venous Thromboembolism. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society for Thrombosis and Haemostasis Research, Medizinische Universität Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICI) are widely used in cancer therapy, but biomarkers for thromboembolic risk, treatment response, and survival remain limited. We evaluated the association of systemic inflammatory indices with these clinical outcomes.

Methods

In this retrospective cohort study, 580 ICI‐treated patients at the Medical University of Vienna, Austria, were included. Inflammatory indices including neutrophil‐lymphocyte‐ratio (NLR), platelet‐lymphocyte‐ratio (PLR), lymphocyte‐monocyte‐ratio (LMR), systemic immune‐inflammation‐index (SII) and C‐reactive‐protein‐albumin‐ratio (CAR) were calculated at ICI‐start and longitudinally within 3 months. Co‐primary outcomes were risk of venous thromboembolism (VTE), assessed using competing risk analysis, and overall‐ and progression‐free‐survival (OS/PFS), evaluated with Cox regression, whereas longitudinal biomarker dynamics were analysed using time‐dependent analyses.

Results

Higher baseline NLR (HR 1.65, 95% CI: 1.28–2.12), CAR (HR 1.99, 95% CI: 1.67–2.38), and SII (HR 1.18, 95% CI: 1.00–1.39) were independently associated with shorter OS, while higher LMR (HR 0.44, 95% CI: 0.30–0.67) was associated with longer survival. For PFS, elevated NLR (HR 1.29, 95% CI: 1.05–1.57), higher PLR (HR 1.18, 95% CI: 1.00–1.39), lower LMR (HR 0.57, 95% CI: 0.43–0.70), and higher CAR (HR 1.42, 95% CI: 1.28–1.62) predicted poorer outcomes. None of the indices at treatment start were associated with VTE, yet doubling of levels within 3 months indicated higher VTE risk for PLR (sub‐distribution hazard ratio [SHR]: 3.03 95% confidence interval [CI]: 1.05–8.08) and a borderline‐significant association for CAR (SHR: 2.02, 95% CI: 0.89–4.60).

Conclusion

We found that selected inflammatory indices were associated with poor OS and PFS in ICI‐treated patients, and longitudinal dynamics might identify patients at higher risk for VTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsInflammationVenous ThromboembolismThromboembolismHumansFemaleRetrospective StudiesMaleAgedMiddle AgedNeutrophilsLymphocytesC-Reactive ProteinProgression-Free SurvivalLymphocyte CountAged, 80 and overMonocytesProportional Hazards ModelsBiomarkersBlood PlateletsAustria

Substanzen

Immune Checkpoint InhibitorsC-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria.
  • Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.
  • Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Dermatology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Leyla Ay, Cihan Ay, Florian Moik

Förderung

  • Society for Thrombosis and Haemostasis Research
  • Medizinische Universität Graz

Zitieren

APA

Ay, L., Pabinger, I., Preusser, M., Berghoff, A. S., Hoeller, C., Ay, C., & Moik, F. (2026). Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70243

Vancouver

Ay L, Pabinger I, Preusser M, Berghoff AS, Hoeller C, Ay C, et al. Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70243

BibTeX
@article{Ay2026,
  author = {Ay, Leyla and Pabinger, Ingrid and Preusser, Matthias and Berghoff, Anna Sophie and Hoeller, Christoph and Ay, Cihan and Moik, Florian},
  title = {Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70243}
}
Kostenlos starten →